用于治疗2型糖尿病的利拉格卢提德输送系统的现状
Riti Chatterjee1, Vishal Sangita Babasaheb Galave1, Anil B Jindal2
1Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Drug delivery and translational research
|September 6, 2025
概括
作为GLP-1受体激动剂的新药输送系统旨在改善糖尿病治疗. 先进的配方显示出有前途, 但面临制造和监管障碍,
科学领域:
- 制药科学
- 生物技术
- 代谢疾病
背景情况:
- 糖尿病是一个日益严重的全球健康问题,其特点是高血糖和胰岛素抵抗.
- 现有的抗糖尿病药物面临药物耐受性和患者服药等挑战.
- 利拉古是一种GLP-1受体激动剂,对血糖控制,减肥和心血管结果有好处,但需要每天注射.
研究的目的:
- 综合审查利拉格卢提德的先进配方策略.
- 批判性地评估这些新系统的药物动力学和药物动力学特征.
- 评估临床转化状态并确定基于利拉格卢提德的治疗方法的障碍.
主要方法:
- 关于利拉格卢提德配方的科学文献的审查.
- 分析先进的药物输送系统:纳米粒子,纳米载体,微粒子,水凝,微针.
- 对疗效,生物可用性和稳定性的临床前和临床数据的审查.
主要成果:
- 各种先进的输送系统 (纳米粒子,微针等) 增强利拉格卢提德的生物可用性和患者的服药能力.
- 这些系统旨在延长释放,提高稳定性和减少剂量频率.
- 尽管临床前数据充满希望,但存在重大转化挑战,包括制造,无菌性和监管批准.
结论:
- 先进的药物输送系统有助于改善2型糖尿病的利拉格类药物治疗.
- 克服制造,监管和稳定性挑战对于临床成功至关重要.
- 对这些新型平台的进一步研究可以促进基于GLP-1的糖尿病治疗.
相关概念视频
Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
Insulin Formulations: Types and Delivery
269
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
269
Insulin: Dosing Regimen and Adverse Effects
252
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
252
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354


